Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 303

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

1st International consensus guidelines for advanced breast cancer (ABC 1)

Open access
Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., Pagani, O., Senkus, E., Thomssen, C., Aapro, M., Bergh, J., Di Leo, A., El Saghir, N., Ganz, P.A., Gelmon, K., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Leadbeater, M., Mayer, M., Rodger, A., Rugo, H., Sacchini, V., Sledge, G., van’t Veer, L., Viale, G., Krop, I., Winer, E.·2012·The Breast
DOI 10.1016/j.breast.2012.03.003
Open this paper in CoChat — free account

Abstract

The 1st international Consensus Conference for Advanced Breast Cancer (ABC 1) took place on November 2011, in Lisbon. Consensus guidelines for the management of this disease were developed. This manuscript summarizes these international consensus guidelines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.breast.2012.03.003

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 105

  1. Cardoso, 2009, Metastatic breast cancer patients: the forgotten heroes!, The Breast, 18, 271, 10.1016/j.breast.2009.09.001 · DOI
  2. Largillier, 2008, Prognostic factors in 1038 women with metastatic breast cancer, Ann Oncol, 19, 2012, 10.1093/annonc/mdn424 · DOI · Paper page
  3. Andre, 2004, Breast cancer with Synchronous metastases: trends in survival during a 14-Year Period, J Clin Oncol, 22, 3302, 10.1200/JCO.2004.08.095 · DOI · Paper page
  4. Sundquist, 2010, Trends in survival in metastatic breast cancer, Eur J Cancer, 8, 191, 10.1016/S1359-6349(10)70474-2 · DOI
  5. Foukakis, 2011, Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden, Breast Cancer Res Treat, 10.1007/s10549-011-1594-z · DOI
  6. Goldhirsch, 2011, Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011, Ann Oncol, 22, 1736, 10.1093/annonc/mdr304 · DOI · Paper page
  7. Harris, 2007, American Society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol, 25, 5287, 10.1200/JCO.2007.14.2364 · DOI · Paper page
  8. Hébert-Croteau, 2004, Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer, J Clin Oncol, 22, 3685, 10.1200/JCO.2004.07.018 · DOI
  9. Griggs, 2007, Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens, J Clin Oncol, 25, 2522, 10.1200/JCO.2006.10.2749 · DOI
  10. Hassett, 2008, Selecting high priority quality measures for breast cancer quality improvement, Med Care, 46, 762, 10.1097/MLR.0b013e318178ead3 · DOI
  11. 2007, Metastatic breast cancer: recommendations proposal from the European School of oncology (ESO)–MBC task force, The Breast, 16, 9, 10.1016/j.breast.2006.11.002 · DOI
  12. Cardoso∗, 2009, International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy, J Natl Cancer Inst, 101, 1174, 10.1093/jnci/djp235 · DOI
  13. Pagani∗, 2010, International guidelines for management of metastatic breast cancer (MBC) from the Euro-pean School of oncology (ESO)–MBC task force: can metastatic breast cancer be cured?, J Natl Cancer Inst, 102, 1, 10.1093/jnci/djq029 · DOI · Paper page
  14. Chirgwin, 2010, Does multidisciplinary care enhance the management of advanced breast cancer?: evaluation of advanced breast cancer multidisciplinary team meetings, Oncol Pract, 6, 294, 10.1200/JOP.2010.000017 · DOI
  15. Ueno, 2010, ABC conceptual model of effective multidisciplinary cancer care, Nat Rev Clin Oncol, 7, 544, 10.1038/nrclinonc.2010.115 · DOI
  16. 2000, EUSOMA the Requirements of a specialist breast unit, Eur J Cancer, 36, 2288, 10.1016/S0959-8049(00)00180-5 · doi:10.1016/s0959-8049(00)00180-5
  17. Wilcken, 2008, Chemotherapy in metastatic breast cancer: a summary of all randomised trials reported 2000–2007, Eur J Cancer, 44, 2218, 10.1016/j.ejca.2008.07.019 · doi:10.1016/j.ejca.2008.07.019
  18. Cardoso, 2002, Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?, Ann Oncol, 13, 197, 10.1093/annonc/mdf101 · DOI
  19. Burzykowski, 2008, Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer, J Clin Oncol, 26, 1987, 10.1200/JCO.2007.10.8407 · DOI · Paper page
  20. Broglio, 2009, Detecting an overall survival benefit that is derived from progression-free survival, J Natl Cancer Inst, 101, 1642, 10.1093/jnci/djp369 · DOI · Paper page
  21. Takeuchi, 2011, Impact of patient-reported outcomes in oncology: a longitudinal analysis of patient-physician communication, J Clin Oncol, 29, 2910, 10.1200/JCO.2010.32.2453 · DOI
  22. Fallowfield, 2002, Quality of life: a new perspective for cancer patients, Nat Rev Cancer, 2, 873, 10.1038/nrc930 · DOI
  23. Fallowfield, 2011, The value of progression-free survival to patients with advanced cancer nature reviews clinical oncology
  24. Houssami, 2011, Imaging bone metastases in breast cancer: evidence on comparative test accuracy, Ann Oncol
  25. Whitlock, 2001, Imaging of metastatic breast cancer: distribution and radiological assessment at presentation, Clin Oncol (Royal College of Radiologists), 13, 181
  26. Costelloe, 2009, Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis, Lan Oncol, 10, 606, 10.1016/S1470-2045(09)70088-9 · DOI
  27. Pennant, 2010, A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence, Health Technol Asses, 14, 1, 10.3310/hta14500 · DOI
  28. Laura Biganzoli, Hans Wildiers, Catherine Oakman, Lorenza Marotti, Sibylle Loibl, Ian Kunkler, et al. Riccardo Audisio. Management of Elderly Individuals with Breast Cancer: update of the Recommendations of the International Society of Geriatric Oncology (SIOG) and the European Society of Breast Cancer Specialists (EUSOMA). The Lancet Oncology, in press.
  29. Dominici, 2011, Surgery of the primary tumor does not improve survival in stage IV breast cancer, Breast Cancer Res Treat, 129, 459, 10.1007/s10549-011-1648-2 · DOI
  30. Rashaan, 2012, Surgery in metastatic breast cancer: patients with a favorable profile seem to have the most benefit from surgery, Eur J Surg Oncol, 38, 52, 10.1016/j.ejso.2011.10.004 · DOI
  31. Ly, 2010, Local-regional radiotherapy and surgery is associated with a significant survival advantage in metastatic breast cancer patients, Tumori, 96, 947
  32. Neuman, 2010, Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter?, Cancer, 116, 1226, 10.1002/cncr.24873 · DOI
  33. Ruiterkamp, 2011, The role of surgery in metastatic breast cancer, Eur J Cancer, 47, S6, 10.1016/S0959-8049(11)70142-3 · DOI
  34. Wilcken, 2003, Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer, Cochrane Database Syst Rev
  35. Anderson, 2011, Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the breast health Global initiative consensus, 2010, Lancet Oncol, 12, 387, 10.1016/S1470-2045(11)70031-6 · DOI · Paper page
  36. El Saghir, 2011, Breast cancer management in low resource countries (LRCs): consensus statement from the breast health Global Initiative, The Breast, 20, S3, 10.1016/j.breast.2011.02.006 · DOI
  37. Bachelot, 2010, TAMRAD: A GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI), Cancer Res, 70
  38. Bhattacharyya, 2011, Reversal of tamoxifen resistance (Hormone resistance) by Addition of Sirolimus (mTOR inhibitor) in metastatic breast cancer, Eur J Cancer, 47
  39. Marty, 2005, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol, 23, 4265, 10.1200/JCO.2005.04.173 · DOI · Paper page
  40. Di Leo, 2008, Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer, J Clin Oncol, 26, 5544, 10.1200/JCO.2008.16.2578 · DOI · Paper page
  41. Zhong-zhen Guan, Binh-he Xu, Wichit Arpornwirat, Zhong-sheng Tong, Vicharn Lorvidhaya, Li Wang, et al. Overall survival benefit Observed with Lapatinib (L) plus Paclitaxel as first-line therapy in patients with HER2-Overexpressing Metastatic Breast Cancer, 2010 CTRC-AACR San Antonio Breast Cancer SymposiumP3-14-24. · doi:10.1158/0008-5472.sabcs10-p3-14-24
  42. Kaufman, 2009, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study, J Clin Oncol, 27, 5529, 10.1200/JCO.2008.20.6847 · DOI · Paper page
  43. Johnston, 2009, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer, J Clin Oncol, 27, 5538, 10.1200/JCO.2009.23.3734 · DOI · Paper page
  44. Cameron, 2008, A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses, Breast Cancer Res Treat, 112, 533, 10.1007/s10549-007-9885-0 · DOI · Paper page
  45. von Minckwitz, 2009, Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study, J Clin Oncol, 27, 1999, 10.1200/JCO.2008.19.6618 · DOI · Paper page
  46. Pegram, 2012, Trastuzumab treatment in multiple lines: current data and future directions, Clin Breast Cancer, 12, 10, 10.1016/j.clbc.2011.07.003 · doi:10.1016/j.clbc.2011.07.003
  47. Blackwell, 2010, Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer, J Clin Oncol, 28, 1124, 10.1200/JCO.2008.21.4437 · DOI · Paper page
  48. Baselga, 2012, NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial, Lancet, 379, 633, 10.1016/S0140-6736(11)61847-3 · DOI · Paper page
  49. Piccart-Gebhart, 2008, Taxanes alone or in combination with anthracyclines As first-line therapy of patients with metastatic breast cancer, J Clin Oncol, 26, 1980, 10.1200/JCO.2007.10.8399 · DOI · Paper page
  50. Stockler, 2011, Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer, J Clin Oncol, 29, 4498, 10.1200/JCO.2010.33.9101 · DOI
  51. Andersson, 2011, Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab As first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2–Positive breast cancer: the HERNATA study, J Clin Oncol, 29, 264, 10.1200/JCO.2010.30.8213 · DOI · Paper page
  52. Jones, 2010, Addition of drug/s to a chemotherapy regimen for metastatic breast cancer, Cochrane Database Syst Rev
  53. Cortes, 2011, Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study, Lancet, 377, 914, 10.1016/S0140-6736(11)60070-6 · DOI · Paper page
  54. Coates, 1987, Improving the quality of life during chemotherapy for advanced breast cancer: Intermittent versus continuous chemotherapy for breast cancer, N Engl J Med, 317, 1490, 10.1056/NEJM198712103172402 · DOI · Paper page
  55. Planchat, 2011, Late lines of treatment benefit survival in metastatic breast cancer in current practice?, The Breast, 20, 574, 10.1016/j.breast.2011.07.010 · doi:10.1016/j.breast.2011.07.010
  56. Banerji, 2007, Factors determining outcome after 3rd line chemotherapy for metastatic breast cancer, The Breast, 16, 359, 10.1016/j.breast.2007.01.004 · doi:10.1016/j.breast.2007.01.004
  57. Kiely, 2010, How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials, J Clin Oncol, 29, 456, 10.1200/JCO.2010.30.2174 · DOI
  58. Gennari, 2011, Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials, J Clin Oncol, 29, 2144, 10.1200/JCO.2010.31.5374 · DOI
  59. Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113 · DOI · Paper page
  60. Miles, 2010, Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer, J Clin Oncol, 28, 3239, 10.1200/JCO.2008.21.6457 · DOI · Paper page
  61. Robert, 2011, RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer, J Clin Oncol, 29, 1252, 10.1200/JCO.2010.28.0982 · DOI · Paper page
  62. O'Shaughnessy, 2011, Iniparib plus chemotherapy in metastatic triple negative breast cancer, N Engl J Med, 364, 205, 10.1056/NEJMoa1011418 · DOI · Paper page
  63. Wong, 2012, Bisphosphonates and other bone agents for breast cancer, Cochrane Library
  64. Van Poznak, 2011, American Society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer, J Clin Oncol, 20, 1221, 10.1200/JCO.2010.32.5209 · DOI · Paper page
  65. Hadji, 2011, Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment, Ann Oncol, 22, 2546, 10.1093/annonc/mdr017 · DOI · Paper page
  66. McQuay, 2008, Radiotherapy for the palliation of painful bone metastases, Cochrane Library
  67. Aapro, 2008, Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel, Ann Oncol, 19, 420, 10.1093/annonc/mdm442 · DOI · Paper page
  68. Zimmer, 1985, Bone tumors: magnetic resonance imaging versus computed tomography, Radiology, 155, 709, 10.1148/radiology.155.3.4001374 · DOI
  69. Avrahami, 1989, Early MR demonstration of spinal metastases in patients with normal radiographs and CT and radionuclide bone scans, J Comput Assist Tomogr, 13, 598, 10.1097/00004728-198907000-00008 · doi:10.1097/00004728-198907000-00008
  70. Jung, 2003, Discrimination of metastatic from acute osteoporotic compression spinal fractures with MR imaging, Radiographics, 23, 179, 10.1148/rg.231025043 · doi:10.1148/rg.231025043
  71. Yuh, 1989, Vertebral compression fractures: distinction between benign and malignant causes with MR imaging, Radiology, 172, 215, 10.1148/radiology.172.1.2740506 · doi:10.1148/radiology.172.1.2740506
  72. Yuh, 1996, Acute vertebral collapse due to osteoporosis or malignancy: appearance on unenhanced and gadolinium-enhanced MR images, Radiology, 199, 541, 10.1148/radiology.199.2.8668809 · doi:10.1148/radiology.199.2.8668809
  73. Abdi, 2005, Metastatic spinal cord syndromes: imaging appearances and treatment planning, Clin Radiol, 60, 637, 10.1016/j.crad.2004.10.011 · doi:10.1016/j.crad.2004.10.011
  74. Godersky, 1987, Use of magnetic resonance imaging in the evaluation of metastatic spinal disease, Neurosurgery, 21, 676, 10.1227/00006123-198711000-00013 · doi:10.1227/00006123-198711000-00013
  75. Dickinson, 2000, Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases, Clin Radiol, 55, 653, 10.1053/crad.2000.0418 · doi:10.1053/crad.2000.0418
  76. George, 2010, Interventions for the treatment of metastatic extradural spinal cord compression in adults, Cochrane Library
  77. Regine, 2003, Metastatic spinal cord compression: a randomized trial of direct decompressive surgical resection plus radiotherapy vs radiotherapy alone, Int J Radiat Oncol Biol Phys, 57, 5125
  78. Townsend, 1994, Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilisation of impending or pathological factors due to metastatic disease, J Clin Oncol, 12, 2345, 10.1200/JCO.1994.12.11.2345 · doi:10.1200/jco.1994.12.11.2345
  79. 1999, The breast specialty group of the British association of surgical oncology. The management of metastatic bone disease in the United Kingdom, Eur J Surg Oncol, 25, 3, 10.1053/ejso.1998.0593 · doi:10.1053/ejso.1998.0593
  80. Cahill, 2011, Trends in survival after surgery for breast cancer metastatic to the brain and spinal column in medicare patients: a population-based analysis, Neurosurgery, 68, 705, 10.1227/NEU.0b013e31820773b2 · doi:10.1227/neu.0b013e31820773b2
  81. Patchell, 1990, A randomized trial of surgery in the treatment of single metastases to the brain, N Engl J Med, 322, 494, 10.1056/NEJM199002223220802 · DOI · Paper page
  82. Noordijk, 1994, The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age, Int J Radiat Oncol Biol Phys, 29, 711, 10.1016/0360-3016(94)90558-4 · doi:10.1016/0360-3016(94)90558-4
  83. Patil, 2010, Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases, Cochrane Database Syst Rev, 10.1002/14651858.CD006121.pub2 · doi:10.1002/14651858.cd006121.pub2
  84. Andrews, 2004, Bahary: whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial, Lancet, 363, 1665, 10.1016/S0140-6736(04)16250-8 · DOI · Paper page
  85. Serizawa, 2010, Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional prospective study, J Neurosurg, 113, 48
  86. Kondziolka, 2011, Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer, J Neurosurg, 114, 792
  87. Patchell, 1998, Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial, JAMA, 280, 1485, 10.1001/jama.280.17.1485 · DOI · Paper page
  88. Aoyama, 2006, Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial, JAMA, 295, 2483, 10.1001/jama.295.21.2483 · DOI · Paper page
  89. Kocher, 2011, Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study, J Clin Oncol, 29, 134, 10.1200/JCO.2010.30.1655 · DOI · Paper page
  90. Chang, 2009, Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial, Lancet Oncol, 10, 1037, 10.1016/S1470-2045(09)70263-3 · DOI · Paper page
  91. Aapro, 2011, 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours, Eur J Cancer, 47, 8, 10.1016/j.ejca.2010.10.013 · DOI · Paper page
  92. Roila, 2010, ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference, Ann Oncol, 21, v232, 10.1093/annonc/mdq194 · DOI · Paper page
  93. Kligman, 2010, Management of hot flashes in women with breast cancer, Curr Oncol, 17, 81, 10.3747/co.v17i1.473 · DOI
  94. Foley, 2011, How well is cancer pain treated?, Palliat Med, 25, 398, 10.1177/0269216311400480 · DOI
  95. Weiss, 2005, Epidemiology of male breast cancer, Cancer Epidemiol Biomarkers Prev, 14, 20, 10.1158/1055-9965.20.14.1 · DOI · Paper page
  96. Ottini, 2003, BRCA1 and BRCA2 mutation Status and tumor Characteristics in male breast cancer: a population-based study in Italy, Cancer Res, 63, 342
  97. Korde, 2010, Multidisciplinary meeting on male breast cancer: summary and research recommendations, J Clin Oncol, 28, 2114, 10.1200/JCO.2009.25.5729 · DOI · Paper page
  98. White, 2011, Male breast carcinoma: increased awareness needed, Breast Cancer Res, 13, 219, 10.1186/bcr2930 · DOI
  99. Speirs, 2010, Problems (and solutions) in the study of male breast cancer, Rare Tumors, 2, 78, 10.4081/rt.2010.e28 · doi:10.4081/rt.2010.e28
  100. Turner, 2000, Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility, J Endocrinol, 164, 225, 10.1677/joe.0.1640225 · DOI
  101. Mauras, 2000, Oestrogen suppression in males: metabolic effects, J Clin Endocrinol Metab, 85, 2370
  102. Trunet, 1993, Open dose finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects, J Clin Endocrinol Metab, 77, 319
  103. Giordano, 2002, Efficacy of anastrozole in male breast. cancer, Am J Clin Oncol, 25, 235, 10.1097/00000421-200206000-00006 · DOI
  104. Doyen, 2010, Aromatase inhibition in male breast cancer patients: biological and clinical implications, Ann Oncol, 21, 1243, 10.1093/annonc/mdp450 · DOI
  105. Giordano, 2006, Leuprolide acetate plus aromatase inhibition for male breast cancer, J Clin Oncol, 24, e42, 10.1200/JCO.2006.07.2397 · DOI

Cited by

See all 303

Metadata

Authors
Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., Pagani, O., Senkus, E., Thomssen, C., Aapro, M., Bergh, J., Di Leo, A., El Saghir, N., Ganz, P. A., Gelmon, K., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Leadbeater, M., Mayer, M., Rodger, A., Rugo, H., Sacchini, V., Sledge, G., van’t Veer, L., Viale, G., Krop, I., & Winer, E.
Venue
The Breast
Publisher
Elsevier BV
Published
2012-06
Volume
21
Issue
3
Pages
242-252
ISSN
0960-9776 (ISSN-L)
DOI
10.1016/j.breast.2012.03.003
OpenAlex
W2171244965
Cited by
303
References
4
FWCI
13.76
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 1st International consensus guidelines for advanced breast cancer (ABC 1). https://app.cochat.ai/papers/10.1016/j.breast.2012.03.003
The paper
Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., Pagani, O., Senkus, E., Thomssen, C., Aapro, M., Bergh, J., Di Leo, A., El Saghir, N., Ganz, P. A., Gelmon, K., . . . Winer, E. (2012). 1st International consensus guidelines for advanced breast cancer (ABC 1). The Breast. https://doi.org/10.1016/j.breast.2012.03.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.